Demant AS
DEMANT: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 189.00 | Npgyls | Mkynmct |
Demant Exits Implants, Expands Presence in China
Business Strategy and Outlook
Demant benefits from favourable trends, including an ageing population, increasing noise pollution, fairly low penetration rates in the developed world, and virtually untapped patient populations in emerging markets. Its broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains. After selling its implant business, Demant is in a better position to focus its efforts and maintain its top-tier positioning in the market.